RALEIGH, N.C., March 16, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced three data presentations from research surrounding BELBUCA ® (buprenorphine) buccal film ...
New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility Endo Pharmaceuticals Inc., a subsidiary ...
Endo announced the launch of Belbuca (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which ...
More Than 115 Million Lives Now Have Preferred Access To BELBUCA In The U.S. RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing ...
DUBLIN , Feb. 22, 2016 /CNW/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP) (ENL.TO), today announced the availability of BELBUCA™ (buprenorphine) buccal film, the first ...
Buprenorphine is a possible solution to the opioid crisis. BioDelivery Sciences' BELBUCA is a brand only product approved for pain management. Shares have almost doubled in the past year, leaving ...
Do not stop using BELBUCA without talking to your healthcare provider. Dispose of expired, unwanted, or unused BELBUCA by removing the BELBUCA film from the foil packaging,and promptly flushing down ...
BioDelivery Sciences International, Inc. (BDSI), a specialty pharmaceutical company, announced that Health Canada, the regulatory authority in Canada, has issued a Notice of Compliance (NoC) approving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback